Opinion|Videos|September 23, 2024
Data on Early Itch Relief with JAK Inhibitors in Atopic Dermatitis
Medical experts review and comment on the effectiveness of oral JAK inhibitors in providing itch relief for patients with atopic dermatitis.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Most patients with atopic dermatitis experience chronic itch; therefore, itch relief is a key treatment goal. Please review and comment on itch relief with oral JAK inhibitors.
Advertisement
Related to this article
For Eczema Awareness Month, Keira Barr, MD, explains the stress-itch cycle in atopic dermatitis and questions to uncover its hidden burden in clinic.
Stephan Weidinger, MD, PhD, discusses 5-year ADlong data showing durable skin clearance and itch control with lebrikizumab in atopic dermatitis.
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.
Participants described how payer requirements and documentation of steroid exposure shape biologic access.
In TRANSCEND-CKD, retatrutide reduced UACR by 49.2% vs placebo and lowered intraglomerular pressure and kidney fat without changing measured GFR at 24 weeks.
Ravulizumab cut proteinuria 43.4% vs placebo at week 34 in I CAN, making it the first C5 inhibitor approved for IgA nephropathy under accelerated approval.
An NHANES analysis finds 82.3% of 9.1 million US adults eligible for kidney-protective GLP-1 RA therapy are unaware of their CKD, with no improvement over a decade.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D
3
Kidney Compass: ORIGIN 3 Final eGFR Data for Atacicept in IgA Nephropathy
4
Sibeprenlimab Stabilizes eGFR Over 24 Months in IgA Nephropathy: VISIONARY
5